-transparent.png){kind=logo}
Herpes simplex virus (HSV) exists in humans in a latent form that can be activated. To characterize the molecular basis of the cell-virus interactions and to analyze the state of the latent HSV genome, an in vitro model system was established. In this system a large fraction of the latently infected cells contain an HSV genome that can be activated. Cell survival was reduced minimally after repression of high multiplicity HSV type 1 (HSV-1) infection of human fibroblast cells with (E)-5-(2-bromovinyl)-2'-deoxyuridine in combination with human leukocyte interferon (IFN-alpha). A minimum of 1 to 3 percent of the surviving cells contained an HSV genome that could be activated either by human cytomegalovirus superinfection or reduction in incubation temperature.
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
January 1993,
Japanese journal of ophthalmology,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
December 2003,
Expert reviews in molecular medicine,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
January 1989,
Lancet (London, England),
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
January 1984,
Clinics in dermatology,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
January 1994,
Gene therapy,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
October 1984,
Proceedings of the National Academy of Sciences of the United States of America,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
January 1977,
Duodecim; laaketieteellinen aikakauskirja,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
February 1973,
Acta microbiologica Academiae Scientiarum Hungaricae,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
October 1977,
Journal of virology,
B L Wigdahl, and
A C Scheck, and
E De Clercq, and
F Rapp
January 1985,
Antiviral research,
